Yazmin Odia is a Neurology physician affiliated with Baptist Hospital of Miami. OpenAlex indexes 311 publications with 2,686 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8479 SW 122nd St
Miami, FL 331565121
Telephone
646-634-9655Provider last certified this registry record 23 Dec 2025.
Clinical trials
- Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Sponsor: Baptist Health South Florida
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20254 payments$15,393openpaymentsdata.cms.gov ↗
- SERVIER PHARMACEUTICALS LLCProgram year20252 payments
- Exelixis Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
59.7%Other antiepileptics31.2%Levetiracetam100%Part D<11 patientsBenzodiazepine14.3%Lorazepam100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
26%Serotonin-3 Receptor Antagonist26%Ondansetron Hcl100%Part D≥12 patientsSensory organs
14.3%Corticosteroid14.3%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
Journal of Clinical Oncology
2024 - An Update on H3K27M-altered Diffuse Midline Glioma: Diagnostic and Therapeutic Challenges in Clinical Practice
Practical Radiation Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Horacio Asbun, MD
Baptist Hospital of Miami
Guilherme Rabinowits, MD
Baptist Hospital of Miami
Rupesh Kotecha, MD
Baptist Hospital of Miami
Juan Viles-Gonzalez, MD
Baptist Hospital of Miami
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”